Cardiorenal syndrome in acute decompensated heart failure

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 2, 2012, Pages 177-189

  Aronson, Doron ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Acute heart failure; Acute kidney injury; Cardiorenal syndromes; Venous congestion; Worsening renal function

Indexed keywords

DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOLAZONE; NESIRITIDE; NEUROHORMONE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; ROLOFYLLINE; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ABDOMINAL PRESSURE; ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; CARDIORENAL SYNDROME; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; ELECTROLYTE DISTURBANCE; HEART FAILURE; HEART OUTPUT; HORMONAL REGULATION; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; ULTRAFILTRATION; UREMIA; VENOUS CONGESTION;

ACUTE DISEASE; ACUTE KIDNEY INJURY; ANIMALS; BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; EARLY DIAGNOSIS; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84856702956     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.193     Document Type: Review

References (130)

1. Ronco C, McCullough P, Anker SD et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 31, 703-711 (2010).
2. Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J. Am. Coll. Cardiol. 53, 589-596 (2009).
3. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the Prospective Outcomes Study in Heart Failure (POSH).Eur. Heart J. 27, 1216-1222 (2006).
4. Metra M, Nodari S, Parrinello G et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur. J. Heart Fail. 10, 188-195 (2008). (Pubitemid 351221392)
5. Voors AA, Davison BA, Felker GM et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur. J. Heart Fail. 13, 961-967 (2011).
6. Goldberg A, Kogan E, Hammerman H, Markiewicz W, Aronson D. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney Int. 76, 900-906 (2009).
7. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 43, 61-67 (2004). (Pubitemid 38045917)
8. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J. Card. Fail. 16, 541-547 (2010).
9. Goldberg A, Hammerman H, Petcherski S et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am. Heart J. 150, 330-337 (2005). (Pubitemid 41116261)
10. Akhter MW, Aronson D, Bitar F et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am. J. Cardiol. 94, 957-960 (2004). (Pubitemid 39349569)
11. Lassus JP, Nieminen MS, Peuhkurinen K et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur. Heart J. 31(22), 2791-2798 (2010).
12. Gottlieb SS, Abraham W, Butler J et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J. Card. Fail. 8, 136-141 (2002). (Pubitemid 34857278)
13. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch. Intern. Med. 168, 987-995 (2008). (Pubitemid 351679639)
14. Blair JE, Pang PS, Schrier RW et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur. Heart J. 32, 2563-2572 (2011).
15. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol. 47, 1987-1996 (2006).
16. Damman K, Navis G, Voors AA et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J. Card. Fail. 13, 599-608 (2007). (Pubitemid 47513536)
17. Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur. J. Heart Fail. 11, 847-854 (2009).
18. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11(2), R31 (2007).
19. Tang WH, Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart 96, 255-260 (2010).
20. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. 47, 76-84 (2006). (Pubitemid 43005168)
21. Newsome BB, Warnock DG, McClellan WM et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch. Intern. Med. 168, 609-616 (2008). (Pubitemid 351468396)
22. Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding Phase IIb study. Lancet 373, 1429-1439 (2009).
23. Massie BM, O'Connor CM, Metra M et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419-1428 (2010).
24. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293, 572-580 (2005). (Pubitemid 40171239)
25. Aronson D, Hammerman H, Beyar R et al. Serum blood urea nitrogen and long-term mortality in acute ST-elevation myocardial infarction. Int. J. Cardiol. 127, 380-385 (2008). (Pubitemid 351888352)
26. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am. J. Med. 116, 466-473 (2004). (Pubitemid 38388616)
27. Klein L, Massie BM, Leimberger JD et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ. Heart Fail. 1, 25-33 (2008).
28. Kazory A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am. J. Cardiol. 106, 694-700 (2010).
29. Coca SG, Parikh CR. Urinary biomarkers for acute kidney injury: perspectives on translation. Clin. J. Am. Soc. Nephrol. 3, 481-490 (2008).
30. Damman K, Van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96, 1297-1302 (2010).
31. Jungbauer CG, Birner C, Jung B et al. Kidney injury molecule-1 and N-acetyl-ssd- glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur. J. Heart Fail. 13, 1104-1110 (2011).
32. Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur. Heart J. 32(21), 2705-2712 (2011).
33. Alvelos M, Pimentel R, Pinho E et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin. J. Am. Soc. Nephrol. 6, 476-481 (2011).
34. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinaseassociated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J. Card. Fail. 16, 49-54 (2010).
35. Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit. Care Med. 36, S75-S88 (2008).
36. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am. Heart J. 138, 285-290. (1999). (Pubitemid 29379679)
37. Nohria A, Hasselblad V, Stebbins A et al. Cardiorenal interactions: insights from the ESCAPE trial. J. Am. Coll. Cardiol. 51, 1268-1274 (2008). (Pubitemid 351400890)
38. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39(Suppl. 4), 10-21; discussion: 22-14 (1990). (Pubitemid 20182861)
39. Rosario LB, Stevenson LW, Solomon SD, Lee RT, Reimold SC. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J. Am. Coll. Cardiol. 32, 1819-1824 (1998). (Pubitemid 29010440)
40. Stevenson LW, Brunken RC, Belil D et al. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J. Am. Coll. Cardiol. 15, 174-180 (1990). (Pubitemid 20034271)
41. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1(8593), 1033-1035 (1988).
42. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J. Am. Coll. Cardiol. 53, 582-588 (2009).
43. Fiksen-Olsen MJ, Strick DM, Hawley H, Romero JC. Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension 19, II137-II141 (1992).
44. Kastner PR, Hall JE, Guyton AC. Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am. J. Physiol. 243, F260-F264 (1982). (Pubitemid 12037813)
45. Gelman S. Venous function and central venous pressure: a physiologic story. Anesthesiology 108, 735-748 (2008). (Pubitemid 351440595)
46. Mohmand H, Goldfarb S. Renal dysfunction associated with intraabdominal hypertension and the abdominal compartment syndrome. J. Am. Soc. Nephrol. 22, 615-621 (2011).
47. De Waele JJ, De Laet I, Kirkpatrick AW, Hoste E. Intra-abdominal hypertension and abdominal compartment syndrome. Am. J. Kidney Dis. 57, 159-169 (2011).
48. Bradley SE, Bradley GP. The effect of increased intra-abdominal pressure on renal function in man. J. Clin. Invest. 26, 1010-1022 (1947).
49. Doty JM, Saggi BH, Sugerman HJ et al. Effect of increased renal venous pressure on renal function. J. Trauma 47, 1000-1003 (1999). (Pubitemid 30007551)
50. Bloomfield GL, Blocher CR, Fakhry IF, Sica DA, Sugerman HJ. Elevated intraabdominal pressure increases plasma renin activity and aldosterone levels. J. Trauma 42, 997-1004; discussion 1004-1005 (1997).
51. Mullens W, Abrahams Z, Skouri HN et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J. Am. Coll. Cardiol. 51, 300-306 (2008).
52. Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang WH. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J. Card. Fail. 14, 508-514 (2008). (Pubitemid 352040863)
53. Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin. J. Am. Soc. Nephrol. 4, 2013-2026 (2009).
54. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol. 54, 1747-1762 (2009).
55. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 121, 2592-2600 (2010).
56. Smilde TD, Damman K, van der Harst P et al. Differential associations between renal function and 'modifiable' risk factors in patients with chronic heart failure. Clin. Res. Cardiol. 98, 121-129 (2009).
57. Smilde TD, Hillege HL, Navis G, Boomsma F, de Zeeuw D, van Veldhuisen DJ. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. Am. Heart J. 148, 165-172 (2004). (Pubitemid 38900497)
58. Zile MR, Bennett TD, St John Sutton M et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 118, 1433-1441 (2008).
59. Aronson D, Eitan A, Dragu R, Burger AJ. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ. Heart Fail. 4, 644-650 (2011).
60. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am. J. Med. 119, S3-S10 (2006). (Pubitemid 44755377)
61. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J. Am. Coll. Cardiol. 56, 1527-1534 (2010).
62. Damman K, Navis G, Smilde TD et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur. J. Heart Fail. 9, 872-878 (2007). (Pubitemid 47332311)
63. Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J. Am. Coll. Cardiol. 39, 1623-1629 (2002). (Pubitemid 34494285)
64. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).Am. Heart J. 138, 849-855 (1999). (Pubitemid 29523271)
65. Ahmed A, Husain A, Love TE et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur. Heart J. 27, 1431-1439 (2006). (Pubitemid 43998077)
66. Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ. Heart Fail. 2, 56-62 (2009).
67. Gheorghiade M, Follath F, Ponikowski P et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur. J. Heart Fail. 12, 423-433 (2010).
68. Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364, 797-805 (2011).
69. Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287, 1541-1547 (2002). (Pubitemid 34269999)
70. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation 108, 492-497 (2003). (Pubitemid 36935545)
71. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation 108, 367-372 (2003). (Pubitemid 36899031)
72. Abraham WT, Adams KF, Fonarow GC et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. 46, 57-64 (2005). (Pubitemid 40905130)
73. Ungar A, Fumagalli S, Marini M et al. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit. Care Med. 32, 1125-1129 (2004). (Pubitemid 38620979)
74. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 117, 200-205 (2008).
75. Beregovich J, Bianchi C, Rubler S, Lomnitz E, Cagin N, Levitt B. Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Am. Heart J. 87, 550-557 (1974).
76. MacGregor DA, Smith TE, Prielipp RC, Butterworth JF, James RL, Scuderi PE. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 92, 338-346 (2000). (Pubitemid 30078329)
77. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann. Intern. Med. 142, 510-524 (2005).
78. Kellum JA, Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit. Care Med. 29, 1526-1531 (2001). (Pubitemid 32762331)
79. Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53, e1-e90 (2009).
80. Goldhaber JI, Hamilton MA. Role of inotropic agents in the treatment of heart failure. Circulation 121, 1655-1660 (2010).
81. Wang DJ, Dowling TC, Meadows D et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110, 1620-1625 (2004). (Pubitemid 39297985)
82. O'Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 365, 32-43 (2011).
83. Mullens W, Abrahams Z, Francis GS et al.q Sodium nitroprusside for advanced low-output heart failure. J. Am. Coll. Cardiol. 52, 200-207 (2008). (Pubitemid 351915785)
84. Dickstein K, Cohen-Solal A, Filippatos G et al. EESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail. 10, 933-989 (2008).
85. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104, 1985-1991 (2001). (Pubitemid 32983246)
86. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am. J. Cardiol. 70, 479-487 (1992).
87. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function following initiation of angiotensin converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ. Heart Fail. 4(6), 685-691 (2011).
88. Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann. Intern. Med. 106, 346-354 (1987). (Pubitemid 17029483)
89. Echemann M, Zannad F, Briancon S et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am. Heart J. 139, 624-631 (2000). (Pubitemid 30207787)
90. Kittleson M, Hurwitz S, Shah MR et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J. Am. Coll. Cardiol. 41, 2029-2035 (2003). (Pubitemid 36677127)
91. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation 110, 1514-1517 (2004). (Pubitemid 39297969)
92. Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 74, 766-774 (1986). (Pubitemid 17186083)
93. Kearney MT, Fox KA, Lee AJ et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J. Am. Coll. Cardiol. 40, 1801-1808 (2002). (Pubitemid 35341959)
94. Gheorghiade M, Abraham WT, Albert NM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZEHF registry. Eur. Heart J. 28, 980-988 (2007). (Pubitemid 47343897)
95. Klein L, O'Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111, 2454-2460 (2005). (Pubitemid 40696133)
96. Goldberg A, Hammerman H, Petcherski S et al. Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction. Am. J. Med. 117, 242-248 (2004). (Pubitemid 39092717)
97. Goldberg A, Hammerman H, Petcherski S et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch. Intern. Med. 166, 781-786 (2006).
98. Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am. J. Cardiol. 95, 14-23 (2005).
99. Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann. Intern. Med. 100, 777-782 (1984). (Pubitemid 14121584)
100. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin- angiotensin system and hyponatremia. N. Engl. J. Med. 310, 347-352 (1984). (Pubitemid 14179539)
101. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73, 257-267 (1986). (Pubitemid 16127402)
102. Mettauer B, Rouleau JL, Bichet D et al. Sodium and water excretion abnormalities in congestive heart failure. Determinant factors and clinical implications. Ann. Intern. Med. 105, 161-167 (1986). (Pubitemid 16039286)
103. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J. Clin. Endocrinol. Metab. 59, 924-930 (1984). (Pubitemid 14020694)
104. Mohammed AA, van Kimmenade RR, Richards M et al. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. Circ. Heart Fail. 3, 354-361 (2010).
105. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J. Am. Coll. Cardiol. 10, 837-844 (1987). (Pubitemid 17163109)
106. Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107, 2690-2696 (2003). (Pubitemid 36667242)
107. Gheorghiade M, Gattis WA, O'Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291, 1963-1971 (2004). (Pubitemid 38544277)
108. Ghali JK, Koren MJ, Taylor JR et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebocontrolled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab. 91, 2145-2152 (2006). (Pubitemid 43854997)
109. Aronson D, Verbalis JG, Mueller M, Krum H. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur. J. Heart Fail. 13, 327-336 (2011).
110. Gheorghiade M, Konstam MA, Burnett JC Jr et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297, 1332-1343 (2007). (Pubitemid 46513234)
111. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319-1331 (2007). (Pubitemid 46513233)
112. Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur. J. Heart Fail. 10, 176-187 (2008).
113. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol. 50, 1551-1560 (2007). (Pubitemid 47532320)
114. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J. Card. Fail. 13, 609-617 (2007). (Pubitemid 47513547)
115. Voors AA, Dittrich HC, Massie BM et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J. Am. Coll. Cardiol. 57, 1899-1907 (2011).
116. Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation 117, 975-983 (2008). (Pubitemid 351272594)
117. Bart BA. Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ. Heart Fail. 2, 499-504 (2009).
118. Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 49, 675-683 (2007). (Pubitemid 46205043)
119. Rogers HL, Marshall J, Bock J et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J. Card. Fail. 14, 1-5 (2008).
120. Shin JT, Dec GW. Ultrafiltration should not replace diuretics for the initial treatment of acute decompensated heart failure. Circ. Heart Fail. 2, 505-511 (2009).
121. Cody RJ, Ljungman S, Covit AB et al. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int. 34, 361-367 (1988).
122. Packer M, Lee WH, Kessler PD.Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 74, 766-774 (1986). (Pubitemid 17186083)
123. Dupont M, Mullens W, Tang WH. Impact of systemic venous congestion in heart failure. Curr. Heart Fail. Rep. 8, 233-241 (2011).
124. Verma A, Anavekar NS, Meris A et al. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J. Am. Coll. Cardiol. 50, 1238-1245 (2007). (Pubitemid 47405128)
125. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J. Am. Coll. Cardiol. 47, 1-8 (2006). (Pubitemid 43005157)
126. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J. Clin. Invest. 83, 336-342 (1989). (Pubitemid 19048443)
127. Levin ER. Endothelins. N. Engl. J. Med. 333, 356-363 (1995).
128. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 324, 473-476 (1986). (Pubitemid 17184166)
129. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N. Engl. J. Med. 339, 321-328 (1998). (Pubitemid 28366422)
130. Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study). http://clinicaltrials.gov/ct2/show/NCT00608491